These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 27142982)

  • 1. Extended likelihood ratio test-based methods for signal detection in a drug class with application to FDA's adverse event reporting system database.
    Zhao Y; Yi M; Tiwari RC
    Stat Methods Med Res; 2018 Mar; 27(3):876-890. PubMed ID: 27142982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zero-inflated Poisson model based likelihood ratio test for drug safety signal detection.
    Huang L; Zheng D; Zalkikar J; Tiwari R
    Stat Methods Med Res; 2017 Feb; 26(1):471-488. PubMed ID: 25189699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Likelihood ratio test-based method for signal detection in drug classes using FDA's AERS database.
    Huang L; Zalkikar J; Tiwari RC
    J Biopharm Stat; 2013; 23(1):178-200. PubMed ID: 23331230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the use of the likelihood ratio test methodology in pharmacovigilance.
    Chakraborty S; Liu A; Ball R; Markatou M
    Stat Med; 2022 Nov; 41(27):5395-5420. PubMed ID: 36177750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Signal detection in FDA AERS database using Dirichlet process.
    Hu N; Huang L; Tiwari RC
    Stat Med; 2015 Aug; 34(19):2725-42. PubMed ID: 25924820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mixture drug-count response model for the high-dimensional drug combinatory effect on myopathy.
    Wang X; Zhang P; Chiang CW; Wu H; Shen L; Ning X; Zeng D; Wang L; Quinney SK; Feng W; Li L
    Stat Med; 2018 Feb; 37(4):673-686. PubMed ID: 29171062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database.
    Szarfman A; Machado SG; O'Neill RT
    Drug Saf; 2002; 25(6):381-92. PubMed ID: 12071774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Criteria revision and performance comparison of three methods of signal detection applied to the spontaneous reporting database of a pharmaceutical manufacturer.
    Matsushita Y; Kuroda Y; Niwa S; Sonehara S; Hamada C; Yoshimura I
    Drug Saf; 2007; 30(8):715-26. PubMed ID: 17696584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statistical methods for exploring spontaneous adverse event reporting databases for drug-host factor interactions.
    Lu Z; Suzuki A; Wang D
    BMC Med Res Methodol; 2023 Mar; 23(1):71. PubMed ID: 36973693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
    Welch HK; Kellum JA; Kane-Gill SL
    Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Subeesh V; Maheswari E; Singh H; Beulah TE; Swaroop AM
    Curr Drug Saf; 2019; 14(1):21-26. PubMed ID: 30362421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Class-imbalanced subsampling lasso algorithm for discovering adverse drug reactions.
    Ahmed I; Pariente A; Tubert-Bitter P
    Stat Methods Med Res; 2018 Mar; 27(3):785-797. PubMed ID: 27114328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An evaluation of statistical approaches to postmarketing surveillance.
    Ding Y; Markatou M; Ball R
    Stat Med; 2020 Mar; 39(7):845-874. PubMed ID: 31912927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mining association patterns of drug-interactions using post marketing FDA's spontaneous reporting data.
    Ibrahim H; Saad A; Abdo A; Sharaf Eldin A
    J Biomed Inform; 2016 Apr; 60():294-308. PubMed ID: 26903152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative performance of two quantitative safety signalling methods: implications for use in a pharmacovigilance department.
    Almenoff JS; LaCroix KK; Yuen NA; Fram D; DuMouchel W
    Drug Saf; 2006; 29(10):875-87. PubMed ID: 16970511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An evaluation of three signal-detection algorithms using a highly inclusive reference event database.
    Hochberg AM; Hauben M; Pearson RK; O'Hara DJ; Reisinger SJ; Goldsmith DI; Gould AL; Madigan D
    Drug Saf; 2009; 32(6):509-25. PubMed ID: 19459718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential use of data-mining algorithms for the detection of 'surprise' adverse drug reactions.
    Hauben M; Horn S; Reich L
    Drug Saf; 2007; 30(2):143-55. PubMed ID: 17253879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors.
    Verden A; Dimbil M; Kyle R; Overstreet B; Hoffman KB
    Drug Saf; 2018 Apr; 41(4):357-361. PubMed ID: 29196988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating medical device adverse event signals using a likelihood ratio test method.
    Xu Z; Xu J; Yao Z; Huang L; Jung M; Tiwari R
    J Biopharm Stat; 2021 Jan; 31(1):37-46. PubMed ID: 32594849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended multi-item gamma Poisson shrinker methods based on the zero-inflated Poisson model for postmarket drug safety surveillance.
    Heo SJ; Jung I
    Stat Med; 2020 Dec; 39(30):4636-4650. PubMed ID: 32910522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.